skip to Main Content

Brisbane, CA, November 25, 2019 – FlemingMartin is pleased to announce that Aimmune Therapeutics, a biopharmaceutical company devoted to improving the lives of people suffering from food allergies, has hired David Berman to be their new Vice President of Business Development.

David brings to Aimmune nearly 20 years of life sciences business development and strategy expertise from his executive roles with Impax Laboratories (formerly NASDAQ: IPXL) and Taro Pharmaceuticals (NYSE: TARO). At both Impax and Taro, David drove revenue and earnings growth, successfully crafted diverse product portfolios, led due diligence, analyzed complex markets, built models, and closed a broad array of licensing agreements, acquisitions, divestitures, and M&A transactions.

Earlier in his career, David managed cross-functional and global teams while trading physical commodities throughout the Asia-Pacific Region for TRAMMO. David earned an M.B.A. from Columbia Business School and received his undergraduate degree from Emory University.

 

Aimmune Therapeutics (NASDAQ: AIMT) is developing oral desensitization treatments to help protect people with potentially life-threatening food allergies. The Company’s first complex biologic product candidate, PALFORZIA™, reduces the frequency and severity of adverse events following exposure to peanut. aimmune.com

 

 

FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards and CEOs to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. flemingmartin.com

Back To Top